Back to News
Market Impact: 0.3
Iovance Biotherapeutics, Inc. Reports 24.6% ORR in Phase 2 IOV-LUN-202 Trial and Plans sBLA in 2027
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Iovance reported that 17 of 69 patients in Cohorts 1 and 2 responded in its Phase 2 trial of lifileucel for previously treated non-squamous metastatic non-small-cell lung cancer, as of the October 14, 2026 data cutoff. The article text is truncated, so further efficacy details and context are unavailable.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
IOVA0.45
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge